Table 5.
Predictors of long-term NLS.
| Category | NLS No (%) 91 (100%) or (Mean ± SD) |
No NLS No (%) 319 (100%) or (Mean ± SD) |
P-value Univariate analysis |
P-value Multivariate analysis |
|---|---|---|---|---|
| Age(days) (Mean ± SD) | 64 ± 12.7 | 71.8 ± 18.4 | 0.000 | >0.05 |
| Age category A (<60 days) B (60–90 days) C (>90 days) |
29 (31.9%) 59 (64.8%) 3 (3.3%) |
61 (19.1%) 166 (52%) 92 (28.8%) |
0.000 | 0.000 |
| Gender Males Females |
38 (41.8%) 53 (58.2%) |
148 (46.4%) 171 (53.6%) |
>0.05 | |
| Type of BA III III, cystic |
80 (87.9%) 11 (12.1%) |
310 (97.2%) 9 (2.8%) |
0.001 | >0.05 |
| Associated anomalies | 2 (2.2%) | 27 (8.5%) | 0.038 | >0.05 |
| BASM | 1 (1.1%) | 12 (3.8%) | >0.05 | |
| Preoperative labs (Mean ± SD) TB(mg/dL) DB(mg/dL) AST(U/L) ALT(U/L) Alka phos(U/L) GGT(U/L) Alb(g/dL) INR Platelets (K/uL) |
11.6 ± 3.3 8.4 ± 2.7 171 ± 83.3 137.5 ± 86 543.6 ± 282.8 1104.8 ± 733.2 3.9 ± 0.5 1 ± 0.04 438.5 ± 158.7 |
12.4 ± 3.7 9.4 ± 3.4 222.1 ± 135.6 159.6 ± 282.4 641.9 ± 274.5 970.7 ± 761.1 3.5 ± 0.6 1.04 ± 0.1 403.4 ± 195.8 |
0.047 0.012 0.001 >0.05 0.004 >0.05 0.000 0.000 >0.05 |
>0.05 >0.05 >0.05 >0.05 0.02 0.09 |
| Portal tracts ductal and/or ductular proliferation Mild Moderate Marked |
75 (82.4%) 16 (17.6%) 0 |
137 (42.9%) 120 (37.6%) 62 (19.4%) |
0.000 | 0.1 |
| Portal tract fibrosis F0 F1 F2 F3 F4 |
6 (6.6%) 68 (74.7%) 17 (18.7%) 0 0 |
11 (3.4%) 122 (38.2%) 127 (39.8%) 40 (12.5%) 19 (6%) |
0.000 | 0.000 |
| Presence of portal tracts macrophages | 28 (30.8%) | 202 (63.3%) | 0.000 | >0.05 |
| Presence of portal tracts giant cells | 5 (5.5%) | 70 (21.9%) | 0.000 | >0.05 |
| Remnant duct size at porta hepatis >150 μm <150 μm No ducts |
73 (80.2%) 16 (17.6%) 2 (2.2%) |
137 (42.9%) 92 (28.8%) 90 (28.2%) |
0.000 | >0.05 |
| Operative bleeding | 0 | 24 (7.5%) | 0.004 | 0.000 |
| Operative time(hours) (Mean ± SD) | 3.6 ± 1 | 4.4 ± 1.1 | 0.000 | 0.08 |
| Postoperative steroids | 63 (69.2%) | 53 (16.6%) | 0.000 | 0.1 |
| Jaundice clearance at 6 months | 84 (92.3%) | 54 (16.9%) | 0.000 | 0.000 |
| Cholangitis | 6 (6.6%) | 169 (53%) | 0.000 | 0.000 |
| PHN | 11 (12.1%) | 228 (71.5%) | 0.000 | 0.000 |
NLS: Native liver survival, BA: Biliary atresia, BASM: Biliary atresia splenic malformation, TB: Total bilirubin, DB: Direct bilirubin, AST: Aspartate transaminase, ALT: Alanine transaminase, Alka phos: Alkaline phosphatase, GGT: Gamma glutamate transferase, Alb: Albumin, INR: International normalization ratio, PHN: Portal hypertension.